Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Randomized, Parallel-group, Rater-blinded Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis Plus a Long Term Extension Period

Next Previous
Trial Profile

A Multi-center, Randomized, Parallel-group, Rater-blinded Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis Plus a Long Term Extension Period

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Teriflunomide (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms TENERE
  • Sponsors Sanofi

Most Recent Events

  • 26 May 2020 Results of pooled analysis from TEMSO, TOWER, TENERE, TOPIC and TERI-PRO assessing lymphocyte levels in teriflunomide-treated patients stratified by age, presented at the 6th Congress of the European Academy of Neurology
  • 06 May 2019 According to a Sanofi Genzyme media release, post-hoc analysis of four clinical studies: a Phase 2 study, Phase III TEMSO, TOWER and TENERE core studies and their extensions, will be presented during the 71st annual meeting of the American Academy of Neurology (AAN) in Philadelphia, PA.
  • 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top